Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y Receptor Inhibitor Treatment in Percutaneous Coronary Intervention.

Sibbing, Dirk; Aradi, Daniel; Alexopoulos, Dimitrios; Ten Berg, Jurrien; Bhatt, Deepak L; Bonello, Laurent; Collet, Jean-Philippe; Cuisset, Thomas; Franchi, Francesco; Gross, Lisa; Gurbel, Paul; Jeong, Young-Hoon; Mehran, Roxana; Moliterno, David J; Neumann, Franz-Josef; Pereira, Naveen L; Price, Matthew J; Sabatine, Marc S; So, Derek Y F; Stone, Gregg W; ... (2019). Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. JACC. Cardiovascular Interventions, 12(16), pp. 1521-1537. Elsevier 10.1016/j.jcin.2019.03.034

[img] Text
Sibbling_Updated Expert Consensus Statement on Platelet Function and Geteic Testing_Elsevier_12062019 in press.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (960kB) | Request a copy

Dual-antiplatelet therapy (DAPT) with aspirin and a P2Y receptor inhibitor is the standard treatment for patients undergoing percutaneous coronary intervention. The availability of different P2Y receptor inhibitors (clopidogrel, prasugrel, ticagrelor) with varying levels of potency has enabled physicians to contemplate individualized treatment regimens, which may include escalation or deescalation of P2Y-inhibiting therapy. Indeed, individualized and alternative DAPT strategies may be chosen according to the clinical setting (stable coronary artery disease vs. acute coronary syndrome), the stage of the disease (early vs. long-term treatment), and patient risk for ischemic and bleeding complications. A tailored DAPT approach may be potentially guided by platelet function testing (PFT) or genetic testing. Although the routine use of PFT or genetic testing in percutaneous coronary intervention-treated patients is not recommended, recent data have led to an update in guideline recommendations that allow considering selective use of PFT for DAPT deescalation. However, guidelines do not expand on when to implement the selective use of such assays into decision making for personalized treatment approaches. Therefore, an international expert consensus group of key leaders from North America, Asia, and Europe with expertise in the field of antiplatelet treatment was convened. This document updates 2 prior consensus papers on this topic and summarizes the contemporary updated expert consensus recommendations for the selective use of PFT or genotyping in patients undergoing percutaneous coronary intervention.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology

UniBE Contributor:

Valgimigli, Marco

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1876-7605

Publisher:

Elsevier

Language:

English

Submitter:

Amanda Valle

Date Deposited:

08 Aug 2019 07:17

Last Modified:

25 Aug 2019 01:32

Publisher DOI:

10.1016/j.jcin.2019.03.034

PubMed ID:

31202949

Uncontrolled Keywords:

P2Y(12) receptor inhibitor genotyping platelet function testing thrombosis

BORIS DOI:

10.7892/boris.131790

URI:

https://boris.unibe.ch/id/eprint/131790

Actions (login required)

Edit item Edit item
Provide Feedback